Skip to main content

Advertisement

SpringerLink
Log in

Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

This study prospectively correlated the level of expression of CD55 on tumours with 7-year survival in 136 colorectal cancer patients. Patients with tumours expressing high levels of CD55 had a significantly worse survival (24%) than patients with low CD55 levels (50%, p<0.02). A similar difference was seen for patients (Duke's B or C) with a high risk of recurrence (29% vs 58%, p<0.05). Furthermore, there was a progressive deterioration in prognosis with increasing antigen expression (p=0.01). It remains unclear if CD55 is overexpressed by tumours to protect them from complement or if it is related to the recent observation that CD55 is a ligand for the T-cell activation antigen CD97. However, it is a marker of aggression, as colorectal cancer patients whose tumours overexpress CD55 have a significantly reduced 7-year survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

References

  1. Amin S, Robins RA, Maxwell-Armstrong C, Scholefield J, Durrant LG (2000) Vaccine induced apoptosis: a novel clinical trial endpoint? Cancer Res 60(12):3132–3136

  2. Armitage NC, Perkins AC, Pimm MV, Farrands PA, Baldwin RW, Hardcastle JD (1984) Localization of an anti-tumour monoclonal antibody (791T/36) in gastrointestinal tumors. Br J Surg 71(6):407–412

    CAS  PubMed  Google Scholar 

  3. Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ, Lee AK (1994) Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal carcinomas. J Natl Cancer Inst 86:681–687

    CAS  PubMed  Google Scholar 

  4. Chu KC, Tarone RE, Chow W et al (1994) Temporal patterns in colorectal cancer incidence, survival and mortality from 1950 through 1990. J Natl Cancer Inst 86:997–1006

    CAS  PubMed  Google Scholar 

  5. Davis LS, Patel SS, Atkinson JP, Lipsky PE (1988) Decay accelerating factor functions as a signal transducing molecule for human T cells. J Immunol 141:2246–2252

    CAS  PubMed  Google Scholar 

  6. Durrant LG, Armstrong CM, Buckley D, Amin S, Robins RA, Carmichael JC et al (2000) A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Clin Cancer Res 62(2):422–430

    Google Scholar 

  7. Durrant LG, Robins RA, Baldwin RW (1989) Flow cytometric screening of monoclonal antibodies for drug or toxin targeting to human cancer. J Natl Cancer Inst 81:688–695

    CAS  PubMed  Google Scholar 

  8. Hamann J, Vogel B, Vanschijndel GMW, Vanlier RAW (1996) The 7-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF) J Exp Med 184(3):1185–1189

  9. Li L, Spendlove I, Morgan J, Durrant LG (2000) CD55 is overexpressed in the tumour environment. Br J Cancer 84(1):80–86

    Google Scholar 

  10. Lindemann F, Schlimok G, Dirschedl P et al (1992) Prognostic significance of micrometastatic tumour cells in the bone marrow of colorectal cancer patients. Lancet 340:685–689

    CAS  PubMed  Google Scholar 

  11. Maxwell-Armstrong CA, Durrant LG, Robins RA, Galvin AM, Scholefield JH, Hardcastle JD (1999) Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotype monoclonal antibody 105AD7. Gut 45:593–598

    CAS  PubMed  Google Scholar 

  12. Moertel CG, Fleming TR, Macdonald JS et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon cariconmas. N Engl J Med 322:352–358

    CAS  PubMed  Google Scholar 

  13. Morgan J, Spendlove I, Durrant LG (2002) The role of CD55 in protecting the tumour environment from complement attack. Tissue Antigens 60(3):213–223

    Article  CAS  PubMed  Google Scholar 

  14. Nicholson-Weller A, Wang C (1994) Structure and function of decay-accelerating factor CD55. J Lab Clin Med 123(4):485–491

    CAS  PubMed  Google Scholar 

  15. Spendlove I, Li L, Carmichael J, Durrant LG (1999) Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Res 59(10):2282–2286

  16. Starzynska T, Marsh PJ, Scholfield PF et al (1994) Prognostic significance of 5T4 oncofetal antigen expression in colorectal adenocarcinomas. Br J Cancer 69:899–902

    Google Scholar 

Download references

Acknowledgements

This work was supported by the Cancer Research Campaign, UK, with a programme grant, no. SP2220/0501.

Author information

Authors and Affiliations

  1. CRC Academic Department of Clinical Oncology, City Hospital, Hucknall Road, Nottingham, Nottinghamshire, NG5 1PB, UK

    L. G. Durrant & I. Spendlove

  2. Department of Surgery, University of Nottingham, Nottingham, UK

    M. A. Chapman, D. J. Buckley & N. C. Armitage

  3. Department of Immunology, University of Nottingham, Nottingham, UK

    R. A. Robins

Authors
  1. L. G. Durrant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. A. Chapman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. J. Buckley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Spendlove
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. A. Robins
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. C. Armitage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. G. Durrant.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Durrant, L.G., Chapman, M.A., Buckley, D.J. et al. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 52, 638–642 (2003). https://doi.org/10.1007/s00262-003-0402-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-003-0402-y

Keywords

Search

Navigation